Effect of inhaled L-arginine on airway nitric oxide in cystic fibrosis patients Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005
Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients Source: Eur Respir J 2001; 17: 1267-1270 Year: 2001
Airway nitric oxide production in patients with cystic fibrosis increases with ivacaftor therapy Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015
Oral L-arginine therapy in patients with cystic fibrosis: a pilot study Source: Eur Respir J 2002; 20: Suppl. 38, 340s Year: 2002
Differences in exhaled nitric oxide levels between patients with cystic fibrosis and atopic bronchial asthma Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013
Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients Source: Eur Respir J 2008; 31: 815-821 Year: 2008
Exhaled nitric oxide is not reduced in infants with cystic fibrosis Source: Eur Respir J 2006; 27: 350-354 Year: 2006
Bronchial but not alveolar nitric oxide is decreased in adults with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 404s Year: 2005
L-Arginine metabolism in airways of children with primary ciliary dyskinesia (PCD) or cystic fibrosis (CF) Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014
Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment Source: Eur Respir J, 53 (5) 1802259; 10.1183/13993003.02259-2018 Year: 2019
Antibiotic treatment decreases exhaled nitric oxide levels in cystic fibrosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 384s Year: 2004
Fractional exhaled nitric oxide levels in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2016 – Asthma, bronchiectasis, and the risk factors for respiratory morbidity Year: 2016
Nasal nitric oxide measurement and a score of key clinical features for the screening of primary ciliary dyskinesia in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Reduced exhaled nitric oxide in infants with cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 384s Year: 2004
Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments Source: Eur Respir J 2009; 34: 117-124 Year: 2009
Inhaled mannitol as treatment for children with cystic fibrosis Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease Year: 2008
Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice Source: Eur Respir J 2011; 37: 72-78 Year: 2011
The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma Source: Eur Respir J 2005; 25: 289-294 Year: 2005
Effects on exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic solution in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 231s Year: 2003
Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases Source: International Congress 2015 – IIPs: orphan Year: 2015